Header cover image

U.K. (FTSE) Biotech Industry Analysis

UpdatedMay 26, 2022
DataAggregated Company Financials
Companies31
  • 7D0.7%
  • 3M-11.6%
  • 1Y-41.6%
  • YTD-40.2%

The Biotech industry has been flat over the last week, but OKYO Pharma has lost 37%. As for the longer term, the industry has declined 42% in the last year. Looking forward, earnings are forecast to grow by 16% annually.

Industry Valuation and Performance

Has the U.K. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Sat, 28 May 2022UK£7.0bUK£1.1b-UK£146,804,240.0038.3x
Mon, 25 Apr 2022UK£7.2bUK£1.1b-UK£91,620,330.0037.9x
Wed, 23 Mar 2022UK£7.4bUK£1.1b-UK£98,687,029.0033x
Fri, 18 Feb 2022UK£8.5bUK£1.1b-UK£119,732,737.0035.3x
Sun, 16 Jan 2022UK£9.7bUK£1.1b-UK£123,388,341.0047.3x
Tue, 14 Dec 2021UK£11.1bUK£1.1b-UK£121,180,343.0054x
Thu, 11 Nov 2021UK£11.9bUK£1.1b-UK£149,832,471.0069.8x
Sat, 09 Oct 2021UK£11.8bUK£1.1b-UK£148,479,118.0068.8x
Mon, 06 Sep 2021UK£12.9bUK£1.1b-UK£143,503,184.6256.7x
Wed, 04 Aug 2021UK£12.1bUK£1.0b-UK£172,541,949.9129.6x
Sat, 08 May 2021UK£11.5bUK£1.0b-UK£166,311,048.5230.3x
Tue, 09 Feb 2021UK£10.8bUK£1.0b-UK£143,994,708.8133.3x
Mon, 02 Nov 2020UK£9.0bUK£985.1m-UK£119,804,987.8160x
Thu, 06 Aug 2020UK£8.2bUK£992.8m-UK£138,646,257.4554.3x
Sun, 10 May 2020UK£7.1bUK£985.7m-UK£114,704,522.8155.7x
Sat, 01 Feb 2020UK£6.4bUK£946.9m-UK£63,951,543.4451.5x
Tue, 05 Nov 2019UK£5.7bUK£925.3m-UK£83,659,311.3054.1x
Fri, 09 Aug 2019UK£5.9bUK£898.8m-UK£94,660,524.0159.6x
Median PE Ratio

56.9x


Total Market Cap: UK£6.1bTotal Earnings: -UK£97,895,948.36Total Revenue: UK£884.5mTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Biotech Industry Median PE3Y Average 49.1x202020212022
Current Industry PE
  • Investors are more pessimistic on the industry, indicating that they anticipate long-term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 38.3x which is lower than its 3-year average PE of 49.1x.
Past Earnings Growth
  • The earnings for companies in the Biotechnology industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 7.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Comparison

How does U.K. Biotech compare with similar industries?

GB Market1.04%
Healthcare2.17%
Biotech0.71%
Biotech0.71%
Industry PEThere is insufficient data on the sub-industries of this industry.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABC AbcamUK£11.721.8%
+UK£48.0m
-17.2%PS609.1x
AVCT Avacta GroupUK£1.2614.9%
+UK£41.6m
-46.7%PS109.2x
GNS GenusUK£27.341.9%
+UK£32.6m
-45.9%PS48.2x
OXB Oxford BiomedicaUK£5.144.4%
+UK£20.7m
-54.9%PS26x
BVXP BioventixUK£37.755.6%
+UK£10.4m
-6.8%PS29.7x
Simply Wall St™
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

GNS

UK£27.34

Genus

7D

1.9%

1Y

-45.9%